HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

F(ab')2 receptor

found on human platelets

Also Known As:

F(ab')2 receptors; framon; receptor, F(ab')2 IgG

Networked: 4 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Membrane Proteins: 10078
    - Cell Surface Receptors: 2125
      - Immunologic Receptors: 9
        F(ab')2 receptor: 4

Experts

1.	Mazurov, A V: 4 articles (01/2005 - 01/2001)
2.	Pevzner, D V: 4 articles (01/2005 - 01/2001)
3.	Staroverov, I I: 4 articles (01/2005 - 01/2001)
4.	Vlasik, T N: 4 articles (01/2005 - 01/2001)
5.	Antonova, O A: 3 articles (01/2005 - 01/2002)
6.	Ruda, M Ia: 3 articles (01/2005 - 01/2001)
7.	Samko, A N: 3 articles (01/2005 - 01/2002)
8.	Khaspekova, S G: 3 articles (12/2002 - 01/2001)
9.	Byzova, T V: 2 articles (12/2002 - 01/2001)
10.	Semenov, A V: 2 articles (12/2002 - 01/2002)

Related Diseases

1.	Hypersensitivity (Allergy) 01/01/2002 - "No signs of individual intolerance and side effects including allergic reactions and bleedings were detected in patients treated with framon. " 12/01/2002 - "In none of the patients did F(ab')(2) FRaMon cause allergic reactions, major bleedings or deep thrombocytopenia. " 01/01/2001 - "F(ab')2 FRaMon (preparation FRAMON) bolus i.v. injection to healthy volunteers at the doses of 0.025-0.2 mg/kg did not induce any signs of individual intolerance, including allergic reactions, bleeding and thrombocytopenia. " 01/01/2005 - "After framon administration there were no allergic reactions or major bleedings, deep thrombocytopenia (< 50000/microl) developed in 1 patient (< 1%), and antibodies against framon were detected in less than 5% of patients. "
2.	Thrombocytopenia (Thrombopenia) 12/01/2002 - "In none of the patients did F(ab')(2) FRaMon cause allergic reactions, major bleedings or deep thrombocytopenia. " 01/01/2001 - "F(ab')2 FRaMon (preparation FRAMON) bolus i.v. injection to healthy volunteers at the doses of 0.025-0.2 mg/kg did not induce any signs of individual intolerance, including allergic reactions, bleeding and thrombocytopenia. " 01/01/2005 - "After framon administration there were no allergic reactions or major bleedings, deep thrombocytopenia (< 50000/microl) developed in 1 patient (< 1%), and antibodies against framon were detected in less than 5% of patients. "
3.	Myocardial Infarction 01/01/2005 - "Number of unfavorable outcomes (cardiovascular death, myocardial infarction, angina recurrence) within 1 month after CA was 3 times higher in control group than in the group of patients treated with framon (11.4% and 3.3%, respectively, p = 0.018). " 01/01/2002 - "The number of endpoints (death, myocardial infarction and indications for repeat revascularization) within 1 year after angioplasty was approximately the same in the groups with framon and abciximab - 7 of 25 (28%) and 7 of 28 (25%), respectively, and more than 1.5 fold higher in the group without GP IIb/IIIa blockers - 12 of 27 (44,4%)."
4.	Thrombosis (Thrombus) 01/01/2005 - "The effect of framon was most strongly pronounced within the first day after procedure -- administration of the drug reduced number of acute thromboses from 6.5% to 0.7% (p = 0.013). "
5.	Hemorrhage 01/01/2001 - "F(ab')2 FRaMon (preparation FRAMON) bolus i.v. injection to healthy volunteers at the doses of 0.025-0.2 mg/kg did not induce any signs of individual intolerance, including allergic reactions, bleeding and thrombocytopenia. "

Related Drugs and Biologics

1.	Platelet Membrane Glycoprotein IIb
2.	Antibodies
3.	Abciximab (ReoPro)